There are currently over 324 generic drugs in our database that covers more than 250 prescribed medications.
Latest News on Generic Drugs
Ranbaxys loss may be a gain for Dr Reddys [Express India]
The delay in Ranbaxy Laboratories getting approval from the USFDA for launching generic version of GlaxoSmithKline's migraine and headache drug Imitrex could turn out to be a gain for Hyderabad-based Dr Reddy's Laboratories, which has already launched the drug in the US.
The delay in Ranbaxy Laboratories getting approval from the USFDA for launching generic version of GlaxoSmithKline's migraine and headache drug Imitrex could turn out to be a gain for Hyderabad-based Dr Reddy's Laboratories, which has already launched the drug in the US.
Imitrex delay: Ranbaxy's loss may be Dr Reddy's gain [Business Standard India]
The delay in Ranbaxy Laboratories getting approval from the USFDA for launching the generic version of GlaxoSmithKline’s (GSK) migraine and headache drug Imitrex could turn out to be a gain for Dr Reddy’s Laboratories, which has already launched the drug in the United States.
The delay in Ranbaxy Laboratories getting approval from the USFDA for launching the generic version of GlaxoSmithKline’s (GSK) migraine and headache drug Imitrex could turn out to be a gain for Dr Reddy’s Laboratories, which has already launched the drug in the United States.
Ranbaxy's loss may be gain for Dr Reddy's [The Hindu]
NEW DELHI: The delay in Ranbaxy Laboratories getting approval from the USFDA for launching generic version of GlaxoSmithKline's (GSK) migraine and headache drug Imitrex could turn out to be a gain for Hyderabad-based Dr Reddy's Laboratories, which has al ready launched the drug in the US.
NEW DELHI: The delay in Ranbaxy Laboratories getting approval from the USFDA for launching generic version of GlaxoSmithKline's (GSK) migraine and headache drug Imitrex could turn out to be a gain for Hyderabad-based Dr Reddy's Laboratories, which has al ready launched the drug in the US.
Challenges persist for embattled drug makers [The Record]
Stricter regulation, a dearth of new blockbuster drugs, increased pressure to lower prices and more intense generic competition hammered the pharmaceutical industry in 2008, but its stocks still weathered the market collapse better than many other sectors.
Stricter regulation, a dearth of new blockbuster drugs, increased pressure to lower prices and more intense generic competition hammered the pharmaceutical industry in 2008, but its stocks still weathered the market collapse better than many other sectors.
Akorn-Strides wins FDA approval for two generic antibiotics [Pharmaceutical Business Review]
Akorn-Strides has announced that the FDA has granted approvals for two abbreviated new drug applications for sterile vancomycin HCl USP, 500mg/vial, 1g/vial and sterile vancomycin HCl USP, 5g/vial pharmacy bulk package.
Akorn-Strides has announced that the FDA has granted approvals for two abbreviated new drug applications for sterile vancomycin HCl USP, 500mg/vial, 1g/vial and sterile vancomycin HCl USP, 5g/vial pharmacy bulk package.